Search
for
Sort by
Research 30 of 1000+
- PD-1+CXCR5−CD4+T cells are correlated with the severity of systemic lupus erythematosus
- Eosinophilic folliculitis of the scalp associated with PD‐1/PDL1 inhibitors
- 183 PD-1 regulatory network is upregulated in contact immunotherapy during alopecia areata treatment
- LB1681 Risk of merkel cell carcinoma progression after treatment discontinuation in patients with an objective response to anti-PD-(L)1 immunotherapy
- PD19-08 MARIJUANA, ALCOHOL, ED AND DEPRESSION: EPIDEMIOLOGIC CORRELATIONS WITH BPH/LUTS
- PD14-05 ECONOMIC IMPLICATIONS OF UROLOGIST PRESCRIPTION PRACTICES AMONG MEDICARE PART D BENEFICIARIES
- PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY
- Predominance of CD27-PD-1- Effector Memory T Cells Re-Expressing CD45RA Characterizes Treatment-Resistant Severe Alopecia Areata
- Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
- Effect of Solvent on Stereoselectivity in Pd/C (Type 39K)-Catalyzed Hydrogenation of Methyl 3-Oxo-4-aza-5-androstene-17-carboxylate, A Key Intermediate for Finasteride and Dutasteride
- 576 INTASYL PH-762: Intratumoral immunotherapy targeting PD-1
- ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
- Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description
- ISID1373 - Expression of programmed cell death 1 inversely correlated with the density of CD8+ T cells infiltrating hair follicles in alopecia areata
- 1373 Expression of programmed cell death 1 inversely correlated with the density of CD8+ T cells infiltrating hair follicles in alopecia areata
- Increased expression of PD‐L1 and PD‐L2 in dermal fibroblasts from alopecia areata mice
- Hair Follicle Mesenchyme-Associated PD-L1 Regulates T-Cell Activation Induced Apoptosis: A Potential Mechanism of Immune Privilege
- Tregs: Where We Are and What Comes Next?
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- Differences in cell subsets between sun-exposed and unexposed skin: preliminary single-cell sequencing and biological analysis from a single case
- Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy
- Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database
- Cutaneous lupus erythematosus induced by tislelizumab
- Recurrent inverse necrotizing infundibular crystalline folliculitis
- A Single-Arm, Open-Label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-Small Cell Lung Cancer
- 575 INTASYL self-delivering RNAi: A flexible platform to treat dermatological malignancies
- IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies